Kandimalla, Ekambar R.

Publishing since 1997 (Senior)

Has published 23 publications in 14 years

Number of publications published per year by Kandimalla, Ekambar R.. (Source : PubMed)

Distribution of publications types for Kandimalla, Ekambar R.. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Conforti A, Cipriani B, Peruzzi D, Dharmapuri S, Kandimalla ER, Agrawal S, Mori F, Ciliberto G, La Monica N, Aurisicchio L. A TLR9 agonist enhances therapeutic effects of telomerase genetic vaccine.  Vaccine  2010  
•  Damiano V, Garofalo S, Rosa R, Bianco R, Caputo R, Gelardi T, Merola G, Racioppi L, Garbi C, Kandimalla ER, Agrawal S, Tortora G. A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action.  Clin. Cancer Res.  2009;15;22  
•  Aurisicchio L, Peruzzi D, Conforti A, Dharmapuri S, Biondo A, Giampaoli S, Fridman A, Bagchi A, Winkelmann CT, Gibson R, Kandimalla ER, Agrawal S, Ciliberto G, La Monica N. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9.  Clin. Cancer Res.  2009;15;5  
•  Lan T, Kandimalla ER, Yu D, Bhagat L, Li Y, Wang D, Zhu F, Tang JX, Putta MR, Cong Y, Trombino AF, Sullivan T, Agrawal S. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8.  Proc. Natl. Acad. Sci. U.S.A.  2007;104;34  
•  Damiano V, Caputo R, Garofalo S, Bianco R, Rosa R, Merola G, Gelardi T, Racioppi L, Fontanini G, De Placido S, Kandimalla ER, Agrawal S, Ciardiello F, Tortora G. TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.  Proc. Natl. Acad. Sci. U.S.A.  2007;104;30  
•  LaCasse EC, Cherton-Horvat GG, Hewitt KE, Jerome LJ, Morris SJ, Kandimalla ER, Yu D, Wang H, Wang W, Zhang R, Agrawal S, Gillard JW, Durkin JP. Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis.  Clin. Cancer Res.  2006;12;17  
•  Trabattoni D, Clivio A, Bray DH, Bhagat L, Beltrami S, Maffeis G, Cesana E, Lowry P, Lissoni F, Kandimalla ER, Sullivan T, Agrawal S, Bartholomew R, Clerici M. Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice.  Vaccine  2006;24;9  
•  Lacasse EC, Kandimalla ER, Winocour P, Sullivan T, Agrawal S, Gillard JW, Durkin J. Application of XIAP antisense to cancer and other proliferative disorders: development of AEG35156/ GEM640.  Ann. N. Y. Acad. Sci.  2005;1058  
•  Kandimalla ER, Bhagat L, Li Y, Yu D, Wang D, Cong YP, Song SS, Tang JX, Sullivan T, Agrawal S. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists.  Proc. Natl. Acad. Sci. U.S.A.  2005;102;19  
•  Wang D, Kandimalla ER, Yu D, Tang JX, Agrawal S. Oral administration of second-generation immunomodulatory oligonucleotides induces mucosal Th1 immune responses and adjuvant activity.  Vaccine  2005;23;20  

[ See timeline ] [ See all publications ]